Enadenotucirev

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameEnadenotucirev
Drug Alias NameEnAdAd11/Ad3 chimeric group B adenovirusOncolytic Ad11/Ad3 chimeric group B adenovirusOncolytic Ad11/Ad3ColoAd-1
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionImmunostimulantsCell death stimulantsAnti-MCP
TargetsMembrane cofactor protein
Therapy Area/IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAkamis Bio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAkamis Bio LtdUniversity Of Oxford
Inactive CompaniesN/A
Active IndicationsRectal NeoplasmsColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4] 
Inactive IndicationsUrinary Bladder NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia